14/04/2025 – AB Science today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease with its lead compound masitinib, based on preclinical data Download PDF Post navigationPreviousPrevious post:Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschNextNext post:European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaRelated PostsAB Science announces EMA approval of Masivet shelf-life extension to 4 yearsJune 9, 2025AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025AB Science announces the successful completion of a EUR 1.8 million private placementMay 20, 2025AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025AB Science reports a new publication in the scientific journal PLOS OneMay 15, 2025CNews – Interview of Alain MoussyMay 12, 2025
AB Science announces the settlement delivery of its latest capital increase for €1.8 millionMay 23, 2025
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025
